相关实验视频
Updated: May 6, 2026

12:03
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
28.6K
对临床益处证据不足的药物的证据开发的覆盖范围:来自荷兰的经验
Jan-Willem Versteeg1, Noraly Stam2, Aukje K Mantel-Teeuwisse1
1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Science, https://ror.org/04pp8hn57Utrecht University, Utrecht, The Netherlands.
International journal of technology assessment in health care
|November 17, 2025
概括
荷兰的证据开发覆盖 (CED) 计划在收集临床数据的同时,为患者提供孤儿药物 (OMP),有条件营销许可 (CMA) 和特殊情况 (AEC) 药物. 促进因素包括利益相关者的参与和个案要求,尽管需要持续评估.
科学领域:
- 卫生政策 卫生政策
- 制药政策 制药政策
- 基于证据的医学基于证据的医学.
背景情况:
- 荷兰国家医疗保健研究所在2019年实施了证据开发覆盖 (CED) 计划.
- 该计划针对具有有限临床益处数据的特定产品,包括孤儿药物 (OMP),有条件营销许可 (CMA) 的药物以及在特殊情况下 (AEC) 获得营销许可的药物.
研究的目的:
- 提供荷兰CED计划的概述.
- 反映该计划的学习,挑战和机会.
- 呈现CED计划的国际视角.
主要方法:
- 对荷兰CED计划的叙述性政策审查.
- 描述计划的各个阶段和利益相关者的参与.
- 包括在CED计划中的药物的概述和国际比较.
主要成果:
- 该CED计划包括四个阶段:预先选,协议起草,协议签署和受控访问.
- 自2019年以来,已有6种药物进入该计划,解决了各种证据缺陷.
- 国际比较显示,类似的药物通常在受限制的补偿计划中使用.
结论:
- 该CED计划促进患者获得OMP,CMA和AEC产品,同时收集临床有效性数据.
- 关键的成功因素包括多方利益相关者的参与",仅在研究中"的数据收集方法,以及灵活的证据要求.
- 由于该计划尚未包括预期的药物数量和未经证实的数据收集实用性,因此需要持续评估.
相关概念视频
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Bioequivalence of Drugs: Drugs with Multiple Indications
231
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
231

